Glonghui, April 15 | Lepu Bio-B (2157.HK) once again increased by more than 13%, rising more than 30% on the 6th. It now reports HK$4.33, hitting a new high of more than 3 months, with a market value of HK$7.2 billion. The company recently announced that Kym, a joint venture with Conoa-B, has signed a license agreement with AstraZeneca to develop and commercialize CMG901. Currently, AstraZeneca has carried out a number of clinical studies on CMG901 treatment for advanced solid tumors. Among them, an international multicenter phase III study comparing CMG901 single drug with the researchers' selected regimen as second-line or higher treatment in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients expressing Claudin 18.2 was announced on the drug clinical trial registration and information platform in March of this year. The first test subjects completed their first dose on April 11. In addition, the company has also established a rich and differentiated pipeline by introducing oncolytic virus products through cooperation.